Opening book details…
Can I read Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials on EtoBox?
Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials by Fei Lu; Yu Hou; Zhengting Chen; Jie Jiang; Xi He; Yaoxiong Xia; Ke Cao; Li Chang; Wenhui Li is a Medicine article available to read on EtoBox.
What is Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials about?
## Background: Triple-negative breast cancer constitutes approximately 12%-17% of all breast cancer cases, and >33% of patients develop distant metastases. Systemic cytotoxic chemotherapy is the primary treatment for patients with metastatic triple-negative breast cancer; however, the role of first-line platinum-based chemotherapy in these patients remains controversial. This meta-analysis evaluated the efficacy and safety of platinum-based first-line chemotherapy for patients with metastatic triple-negative breast cancer. ## Methods: We systematically searched the PubMed, Embase, Cochrane, and Clinical Trials registry databases up to June 1, 2020 to identify randomized controlled trials that investigated platinum-based vs. first-line platinum-free chemotherapy in patients with metastatic triple-negative breast cancer. We used fixed and random effects models to calculate pooled hazard ratios and odds ratios with 95% confidence intervals for progression-free and overall survival, objective response rates, and grade 3 and 4 adverse events. ## Results: Four randomized controlled trials (__N__ = 590 patients) were included. Platinum-based chemotherapy significantly increased the object
Who reads Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Fei Lu; Yu Hou; Zhengting Chen; Jie Jiang; Xi He; Yaoxiong Xia; Ke Cao; Li Chang; Wenhui Li
- Publisher
- SAGE Publications
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)